Milton Mayo Morris Sells 6,293 Shares of Embecta (NASDAQ:EMBC) Stock

Embecta Corp. (NASDAQ:EMBC) Director Milton Mayo Morris sold 6,293 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the completion of the sale, the director directly owned 53,828 shares of the company’s stock, valued at approximately $316,508.64. This trade represents a 10.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Embecta Stock Performance

EMBC opened at $5.12 on Thursday. Embecta Corp. has a fifty-two week low of $2.77 and a fifty-two week high of $15.55. The firm’s fifty day moving average is $4.26 and its 200 day moving average is $5.73. The stock has a market cap of $290.10 million, a price-to-earnings ratio of 3.46 and a beta of 0.86.

Embecta (NASDAQ:EMBC) last issued its earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.29. The company had revenue of $271.70 million during the quarter, compared to the consensus estimate of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. Embecta’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, equities research analysts predict that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be given a dividend of $0.01 per share. The ex-dividend date is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.8%. Embecta’s dividend payout ratio (DPR) is currently 2.70%.

Wall Street Analyst Weigh In

EMBC has been the topic of a number of research analyst reports. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Finally, Bank of America lowered their target price on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a report on Monday, May 18th. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $11.00.

Hedge Funds Weigh In On Embecta

Several institutional investors have recently added to or reduced their stakes in EMBC. Walleye Capital LLC purchased a new stake in Embecta during the first quarter valued at approximately $7,013,000. SG Americas Securities LLC increased its position in shares of Embecta by 138.4% during the 1st quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock valued at $9,184,000 after purchasing an additional 603,106 shares during the last quarter. UBS Group AG increased its position in shares of Embecta by 200.8% during the 4th quarter. UBS Group AG now owns 630,994 shares of the company’s stock valued at $7,496,000 after purchasing an additional 421,254 shares during the last quarter. LSV Asset Management raised its holdings in Embecta by 92.5% during the 4th quarter. LSV Asset Management now owns 552,582 shares of the company’s stock valued at $6,565,000 after buying an additional 265,482 shares during the period. Finally, Jefferies Financial Group Inc. raised its holdings in Embecta by 24.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 2,354,971 shares of the company’s stock valued at $27,977,000 after buying an additional 470,096 shares during the period. Hedge funds and other institutional investors own 93.83% of the company’s stock.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.